

Mehmet Samur

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7170840/mehmet-samur-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

1,879
citations

22
h-index

43
g-index

102
ext. papers

2,741
ext. citations

5.6
avg, IF

4.35
L-index

#	Paper	IF	Citations
92	Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. <i>JAMA Oncology</i> , 2017 , 3, 28-35	13.4	273
91	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4607-18	12.9	214
90	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018 , 132, 587-597	2.2	196
89	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019 , 33, 159-170	10.7	176
88	Genomic patterns of progression in smoldering multiple myeloma. <i>Nature Communications</i> , 2018 , 9, 3363	7.4	99
87	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019 , 10, 3835	17.4	94
86	Widespread intronic polyadenylation diversifies immune cell transcriptomes. <i>Nature Communications</i> , 2018 , 9, 1716	17.4	66
85	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 5988-5999	7.8	62
84	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016 , 7, 10258	17.4	61
83	Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. <i>Nature Communications</i> , 2021 , 12, 868	17.4	54
82	Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 4280-4289	12.9	44
81	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014 , 124, 3110-7	2.2	42
80	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. <i>Blood</i> , 2018 , 132, 1050-1063	2.2	40
79	Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. <i>Oncotmunology</i> , 2016 , 5, e1189052	7.2	36
78	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. <i>Blood Advances</i> , 2018 , 2, 2937-2946	7.8	36
77	Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. <i>Leukemia</i> , 2020 , 34, 196-209	10.7	32
76	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018 , 32, 2626-2635	10.7	31

75	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017 , 129, 1308-1319	2.2	26
74	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. <i>Blood</i> , 2017 , 129, 2233-2245	2.2	25
73	Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1744-1754	6.1	25
72	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 39	7	25
71	Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance. <i>Blood Cancer Journal</i> , 2018 , 8, 92	7	23
70	MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , 2019 , 79, 5711-5722	10.1	22
69	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3107-3118	2.2	19
68	Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. <i>Onc Immunology</i> , 2014 , 3, e970914	7.2	18
67	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. <i>Blood Cancer Discovery</i> , 2021 , 2, 468-483	7	15
66	MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. <i>Oncogene</i> , 2019 , 38, 7266-7277	7.7	11
65	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. <i>Cell Reports</i> , 2018 , 25, 3693-3705.e6	10.6	11
64	Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR γ , decreases murine spontaneous intestinal tumorigenesis. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 13-24	7.4	10
63	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). <i>Blood</i> , 2018 , 132, 2778-2780	2.2	10
62	Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 3968-3972	7.8	8
61	Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 14-14	2.2	7
60	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 4-5	2.2	6
59	LSD1 Impairs the Epithelial-Mesenchymal Transition (EMT) and Osteoclastogenesis Potency in Multiple Myeloma and Synergistically Induces Cytotoxicity with HDAC Inhibitors. <i>Blood</i> , 2014 , 124, 3410-3410	2.2	4
58	Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021 , 2, 370-387	7	4

57	YWHAE/14-3-3 σ expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. <i>Blood</i> , 2020 , 136, 468-479	2.2	3
56	Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM). <i>Blood</i> , 2019 , 134, 4742-4742	2.2	3
55	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. <i>Blood</i> , 2012 , 120, 2932-2932	2.2	3
54	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Blood Advances</i> , 2018 , 2, 2400-2411	7.8	3
53	Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.. <i>Nature Communications</i> , 2022 , 13, 807	17.4	2
52	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. <i>Blood</i> , 2020 , 136, 7-8	2.2	2
51	Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance. <i>Blood</i> , 2015 , 126, 2420-2420	2.2	2
50	Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition. <i>Blood</i> , 2015 , 126, 504-504	2.2	2
49	Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 116-116	2.2	2
48	Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 166	7	2
47	Multiple Myeloma DREAM Challenge Reveals Epigenetic RegulatorPHF19As Marker of Aggressive Disease		2
46	Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application. <i>Blood</i> , 2019 , 134, 134-134	2.2	2
45	Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition. <i>Blood</i> , 2020 , 136, 33-34	2.2	1
44	Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability. <i>Blood</i> , 2014 , 124, 3417-3417	2.2	1
43	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014 , 124, 638-638	2.2	1
42	Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 721-721	2.2	1
41	Functional and Clinical Impact of Splicing Factor Dysregulation in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 726-726	2.2	1
40	The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact. <i>Blood</i> , 2015 , 126, 835-835	2.2	1

39	A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications. <i>Blood</i> , 2016 , 128, 356-356	2.2	1
38	Dysregulated Aid/Apobec Family Proteins Promote Genomic Instability in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 803-803	2.2	1
37	IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. <i>Blood</i> , 2021 , 138, 1980-1985	2.2	1
36	Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells. <i>Blood</i> , 2021 , 138, 2655-2655	2.2	1
35	Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC. <i>Blood</i> , 2017 , 130, 64-64	2.2	1
34	Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control. <i>Blood</i> , 2018 , 132, 4500-4500	2.2	1
33	Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. <i>Blood Cancer Journal</i> , 2021 , 11, 13	7	1
32	Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models. <i>Blood</i> , 2020 , 136, 21-22	2.2	0
31	Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 40-40	2.2	0
30	Functional dissection of inherited non-coding variation influencing multiple myeloma risk.. <i>Nature Communications</i> , 2022 , 13, 151	17.4	0
29	Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern. <i>Blood</i> , 2016 , 128, 2088-2088	2.2	0
28	Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 545-545	2.2	0
27	CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways. <i>Oncotarget</i> , 2021 , 12, 2323-2337	3.3	0
26	Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. <i>Communications Biology</i> , 2021 , 4, 617	6.7	0
25	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 20-21	2.2	
24	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020 , 136, 8-8	2.2	
23	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. <i>Blood</i> , 2020 , 136, 31-31	2.2	
22	Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 49-49	2.2	

- 21 Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature. *Blood*, **2020**, 136, 7-8 2.2
- 20 Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. *Blood*, **2020**, 136, 1-2 2.2
- 19 Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13. *Blood*, **2020**, 136, 39-39 2.2
- 18 B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication. *Blood*, **2021**, 138, 2670-2670 2.2
- 17 16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p. *Blood*, **2021**, 138, 1590-1590 2.2
- 16 Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2021**, 138, 1127-1127 2.2
- 15 Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability. *Blood*, **2021**, 138, 2687-2687 2.2
- 14 PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. *Blood*, **2017**, 130, 648-648 2.2
- 13 Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications. *Blood*, **2018**, 132, 1925-1925 2.2
- 12 HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma. *Blood*, **2019**, 134, 4385-4385 2.2
- 11 Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM). *Blood*, **2014**, 124, 2055-2055 2.2
- 10 Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2. *Blood*, **2014**, 124, 4714-4714 2.2
- 9 Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma. *Blood*, **2014**, 124, 642-642 2.2
- 8 Differential and Limited Expression of Mutant Alleles in Multiple Myeloma. *Blood*, **2014**, 124, 2007-2007 2.2
- 7 Functional and Genomic Signatures of Homologous Recombination (HR) Predict for Clinical Outcome in Multiple Myeloma (MM). *Blood*, **2015**, 126, 3626-3626 2.2
- 6 Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish. *Blood*, **2015**, 126, 1431-1431 2.2
- 5 Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma. *Blood*, **2015**, 126, 4187-4187 2.2
- 4 Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma. *Blood*, **2015**, 126, 838-838 2.2

- 3 Deubiquitylating Enzyme USP1 As Therapeutic Target in Multiple Myeloma. *Blood*, **2016**, 128, 3290-3290.2.2
- 2 Flap Structure-Specific Endonuclease 1 (FEN1) May be a Key Mediator of Genome Instability in Myeloma: A Cellular Vulnerability with Potential Therapeutic Significance. *Blood*, **2016**, 128, 4440-4440 2.2
- 1 Studying Evolution of Multiple Myeloma with CanEvolve. *Blood*, **2011**, 118, 2886-2886 2.2